# US 2023/0265444 A1 · Gene-editing in cannabis plant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265444 A1
- Document ID: US20230265444A1
- Status: Published application
- Kind: A1
- Application number: 18/174,103
- Filed: 2023-02-24
- Published: 2023-08-24
- Earliest claimed: 2022-02-24
- Assignees: Canopy Growth Corporation
- Applicants: Canopy Growth Corporation
- Inventors: Daniel Kevin FOWLER
- Web page: https://patentgrep.com/patent/US20230265444A1

## CPC

- C12N 15/8202: {by biological means, e.g. cell mediated or natural vector}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/8213: {Targeted insertion of genes into the plant genome by homologous recombination}
- C12N 15/8218: {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
- C12N 15/8243: {involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present technology is in the field of molecular biology and plant biology, particularly as it pertains to gene editing in plants of the genus Cannabis. More specifically, there are provided systems and methods for targeted DNA modifications and gene editing in Cannabis plant, including systems and methods for making such modifications using a CRISPR/Cas-system nuclease complex, kits comprising the CRISPR/Cas-system nuclease complex, and constructs encoding the same.

## Claims

### Claim 1

A method for genetically editing a target gene in the genome of cells from a Cannabis plant, the method comprising:
(a) introducing one or more exogenous nucleic acid having gene-editing activity into the cells;
(b) optionally, cultivating the cells under conditions allowing gene-editing of the target gene in the genome of said cells; and
(c) optionally, selecting cells which have been gene-edited by the gene-editing activity of the one or more exogenous nucleic acid molecule.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more exogenous nucleic acid molecule is a DNA.

### Claim 3 (depends on 2)

The method of claim 2, wherein the DNA is an expression vector.

### Claim 4 (depends on 1)

The method of claim 1, wherein the one or more exogenous nucleic acid molecule is an RNA.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more exogenous nucleic acid molecule encodes a CRISPR endonuclease.

### Claim 6 (depends on 5)

The method of claim 5, wherein the CRISPR endonuclease is a Cas enzyme, optionally selected from Cas9, Cas12, Cas12a, Cas13a, Cpf1, Csm1, CasX, and CasY.

### Claim 7 (depends on 6)

The method of claim 6, wherein the Cas enzyme is Cas9, optionally selected from SpCas9, SaCas9, SauriCas9, StCas9, NmCas9, and FnCas9.

### Claim 8 (depends on 7)

The method of claim 7, wherein the Cas9 is SpCas9-NLS.

### Claim 9 (depends on 6)

The method of claim 6, wherein the Cas enzyme is Cas12, optionally Cas12a, optionally selected from AsCas12a, FnCas12a, and LbCas12a.

### Claim 10 (depends on 9)

The method of claim 9, wherein the Cas12 is LbCas12a-NLS.

### Claim 11 (depends on 1)

The method of claim 1, wherein the one or more exogenous nucleic acid molecule encodes a guide RNA, optionally selected from a crRNA, a tracrRNA, an sgRNA, and combinations thereof.

### Claim 12 (depends on 4)

The method of claim 4, wherein the one or more exogenous nucleic acid molecule is a guide RNA, optionally selected from a crRNA, a tracrRNA, an sgRNA, and combinations thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein the guide RNA comprises or consists of the sequence set forth in any one of SEQ ID NOs: 1-42, or has at least, greater than or about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.

### Claim 14 (depends on 13)

The method of claim 13, wherein the guide RNA has the sequence set forth in any one of SEQ ID NOs: 1-42.

### Claim 15 (depends on 11)

The method of claim 11, wherein the guide RNA binds the target gene in the genome of the cells, wherein the target gene is CBDAS, CBCAS, R3-MYB1, R3-MYB2, R3-MYB3, R3-MYB4, or eIF4e.

### Claim 16 (depends on 1)

The method of claim 1, wherein the target gene is CBDAS, CBCAS, R3-MYB1, R3-MYB2, R3-MYB3, R3-MYB4, eIF4e, or a combination thereof.

### Claim 17 (depends on 1, 6, 11)

The method of claim 1, wherein the one or more exogenous nucleic acid molecule comprises a first exogenous nucleic acid molecule and a second exogenous nucleic acid molecule, the first exogenous nucleic acid molecule encoding the CRISPR endonuclease as defined in claim 6, and the second exogenous nucleic acid molecule encoding the guide RNA as defined in claim 11.

### Claim 18 (depends on 1)

The method of claim 1, wherein said step of introducing one or more exogenous nucleic acid having gene-editing activity into the cells comprises transformation, optionally transformation via a DNA virus, via an RNA virus, via protoplasts, via T-DNA delivery or via particle bombardment.

### Claim 19 (depends on 18)

The method of claim 18, wherein said transformation comprises transformation with an Agrobacterium carrying said one or more exogenous nucleic acid molecule.

### Claim 20 (depends on 18)

The method of claim 18, wherein said transformation comprises transformation via biolistic transformation.
